12:00 AM
 | 
Mar 27, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Generx: Phase I/II

CLTX said that preliminary results from its 67-patient placebo-controlled U.S. Phase I/II AGENT trial showed that Generx was safe and well tolerated at all doses and improved treadmill exercise time at multiple dose...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >